Drugs / CKD-341
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06281132 | Mar → May 2024 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05921435 | Jun → Sep 2023 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT05571813 | Nov → Dec 2022 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-341 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06281132 ↗ |
| Route | Oral | “Oral” NCT05921435 ↗ |